MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
Rhea-AI Summary
MindMaze Therapeutics (RLFTF) announced on March 19, 2026 that Baader Bank has initiated equity research coverage with a Buy recommendation and a CHF 1.80 target price.
According to the company, this new coverage complements existing research from Edison Group, which values the company at CHF 3.56 per share.
Positive
- Baader Bank initiated coverage with a Buy recommendation
- New analyst coverage may increase visibility and liquidity for RLFTF shares
Negative
- Target price divergence: Baader CHF 1.80 vs Edison CHF 3.56
Key Figures
Market Reality Check
Peers on Argus
RLFTF gained 2.5% while peers were mixed: one notable gainer at +1.93% and one decliner at -0.85%, with others flat. This points to stock-specific impact from the new research coverage.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Reimbursement strategy | Positive | -6.1% | Outlined global reimbursement push with SwissNeuroRehab and U.S. CMS coding. |
| Dec 15 | Business combination | Positive | -57.5% | Closed NeuroX combination, creating integrated neurotherapeutics platform with new shares. |
| Nov 14 | Deal approval | Positive | +0.5% | Shareholders approved NeuroX combination and capital increase for new structure. |
| Oct 29 | Clinical results | Positive | +1.5% | Reported positive pivotal bioequivalence results for RLF-OD032 vs KUVAN. |
Recent news shows mixed reactions: strategic and clinical positives sometimes aligned with gains but also saw notable selloffs on major corporate transactions.
Over the past months, the company transitioned from Relief Therapeutics to MindMaze Therapeutics via a business combination, issuing 140,000,000 new shares and reaching 152,602,044 shares outstanding. It reported positive pivotal bioequivalence data for RLF-OD032 with plans for a 505(b)(2) NDA and a planned 10-month FDA review. A global reimbursement strategy highlighted a CHF 11.2 million SwissNeuroRehab program and 27+ clinical studies. Against this backdrop, today’s initiation of coverage adds external validation rather than a new operational milestone.
Market Pulse Summary
This announcement adds external validation through Baader Bank’s Buy rating and a target of CHF 1.80, alongside Edison Group’s valuation at CHF 3.56. It follows a period of major change, including the NeuroX business combination and positive clinical data for RLF-OD032 with a planned 10-month FDA review. Investors may focus on how coverage assessments incorporate prior dilution from 140,000,000 new shares, the CHF 11.2 million SwissNeuroRehab program, and the company’s 27+ completed studies.
AI-generated analysis. Not financial advice.
GENEVAD, SE / ACCESS Newswire / March 19, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares.
Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company at CHF 3.56 per share.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company's FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.
For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com
Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company's ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
What did MindMaze Therapeutics (RLFTF) announce on March 19, 2026?
What is Baader Bank's recommendation and target price for RLFTF?
How does Baader Bank's CHF 1.80 target compare to Edison's valuation for RLFTF?
Could Baader Bank's coverage affect MindMaze Therapeutics (RLFTF) stock trading?
Does the announcement change MindMaze Therapeutics' guidance or financials for RLFTF?
